KRBOX1 Inhibitors
KRBOX1 inhibitors encompass various chemical entities that decrease the functional activity of KRBOX1 by selectively impeding distinct signaling cascades within the cell. Compounds such as Rapamycin, LY 294002, and Wortmannin exert their inhibitory influence on KRBOX1 by targeting the mTOR pathway, a crucial regulator of cellular proliferation and growth signals that KRBOX1 is implicated in. Rapamycin specifically binds to mTOR, attenuating its kinase activity, which cascades down to a subdued functional state of KRBOX1. LY 294002 and Wortmannin serve a similar purpose by inhibiting PI3K, thereby disrupting the PI3K/AKT/mTOR signaling axis and consequentially diminishing KRBOX1 activity due to its reliance on downstream mTOR signaling cues.
Further, KRBOX1 activity is susceptible to modulation by inhibitors of the MAPK pathway, such as PD 98059, SP600125, SB 203580, and U0126, which target MEK, JNK, p38 MAPK, and MEK/ERK, respectively, each potentially curtailing KRBOX1 function if it is subject to regulation by these kinases. Sorafenib and Dasatinib, both tyrosine kinase inhibitors, could also suppress KRBOX1 activity by obstructing kinase-mediated signaling pathways that are contributory to KRBOX1 function. Additionally, Trametinib, a MEK1/2 inhibitor, and PD 0332991, a CDK4/6 inhibitor, may lead to a reduction in KRBOX1 activity by blocking cell cycle-related kinases that could influence KRBOX1's role in cell cycle progression. Lastly, Nutlin-3, which activates p53 by preventing its interaction with MDM2, could result in a downregulation of KRBOX1 through a feedback inhibition mechanism, assuming KRBOX1 activity is affected by p53 signaling pathways. Together, these inhibitors embody a spectrum of chemical interventions that indirectly suppress KRBOX1 activity by strategically targeting various signaling nodes and pathways upstream of KRBOX1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to and inhibits mTOR (mechanistic target of rapamycin), a protein kinase involved in cell growth, proliferation, and survival. KRBOX1, as part of the pathway regulated by mTOR, may experience dampened activity due to the reduction in proliferative signaling that rapamycin induces. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K (phosphoinositide 3-kinases), which leads to the blockade of the PI3K/AKT/mTOR pathway. By inhibiting this pathway, LY 294002 would indirectly diminish the activity of KRBOX1, which is downstream of mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. It impairs the PI3K/AKT/mTOR pathway, leading to indirect inhibition of KRBOX1 due to decreased activation of mTOR-related processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD 98059 could indirectly lead to decreased activity of KRBOX1 if KRBOX1 is regulated via ERK-dependent signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is part of the MAPK pathway. If KRBOX1 activity is modulated through JNK signaling, inhibiting JNK with SP600125 would lead to a reduction in KRBOX1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is known to inhibit p38 MAPK. If KRBOX1 functions are influenced by p38 MAPK signaling, the use of SB203580 could indirectly inhibit KRBOX1 by reducing p38 MAPK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that prevents the activation of MAPK/ERK. If KRBOX1 is regulated by the MAPK/ERK pathway, U0126 would result in decreased KRBOX1 activity through inhibition of this signaling cascade. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases. By inhibiting these kinases, Sorafenib can disrupt signaling pathways that, if involving KRBOX1, would result in diminished KRBOX1 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a potent tyrosine kinase inhibitor. By inhibiting tyrosine kinases, Dasatinib could interfere with signaling pathways that regulate KRBOX1, leading to a decrease in its activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is an inhibitor of MEK1 and MEK2. Inhibition of these kinases could lead to reduced activity of KRBOX1 if it is regulated by the MEK/ERK signaling pathway. | ||||||